SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer.
Yuxin ChenHai LiWeiwei LiangYan GuoMiaoguan PengWen KeHaipeng XiaoHongyu GuanYanbing LiPublished in: Journal of cellular biochemistry (2021)
Solute Carrier Family 6 Member 15 (SLC6A15), a sodium-dependent neutral amino acid transporter, has been found with dysregulated expression in several kinds of cancers. However, the expression pattern and the biological functions of SLC6A15 in papillary thyroid cancer (PTC) remain unknown. In this study, we found that SLC6A15 was downregulated in PTC, which was related to N classification. Ectopic overexpression of SLC6A15 impaired migratory and invasive abilities of PTC cell in vitro. In addition, we identified intercellular adhesion molecule-1, a vital oncogene in thyroid cancer progression, was involved in the effects of SLC6A15 on PTC cell. These results indicate that SLC6A15 acts as a tumor suppressor and might be a potential therapeutic target in the treatment of PTC.
Keyphrases
- papillary thyroid
- lymph node metastasis
- poor prognosis
- single cell
- amino acid
- cell therapy
- endothelial cells
- machine learning
- cell proliferation
- squamous cell carcinoma
- deep learning
- binding protein
- escherichia coli
- staphylococcus aureus
- young adults
- human health
- risk assessment
- induced pluripotent stem cells
- pluripotent stem cells
- combination therapy
- smoking cessation